Enfiera 500 mg Injection
  1. Home
  2. Pharma Products
  3. Cadila Healthcare Ltd
  4. Enfiera 500 mg Injection

Enfiera 500 mg Injection

Enfiera 500 mg Injection contains rituximab, a monoclonal antibody used to treat certain blood cancers and autoimmune disorders. It is supplied as 500 mg/50 mL concentrate for solution for infusion and is administered intravenously under medical supervision. Rituximab targets the CD20 protein on B-cells and helps the immune system destroy abnormal B-cells.

BUY NOW

Category

Enfiera 500 mg Injection is used in treatment regimens for non-Hodgkin lymphoma and chronic lymphocytic leukemia, and may also be prescribed for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris. Rituximab selectively binds to CD20-positive B-cells, resulting in their depletion and helping control abnormal or overactive immune responses. The medicine is administered as an intravenous infusion by a qualified healthcare professional according to the prescribed protocol. Patients require monitoring for infusion reactions, infections, hepatitis B reactivation, and other treatment-related complications.

Technical Specification

Specification Details
Active Ingredient Rituximab
Strength 500 mg
Concentration 10 mg/mL
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Pack Size 1 Vial, 50 mL

Product Also Known As

Enfiera 500 mg Injection, Enfiera 500 Injection, Rituximab 500 mg Injection, Rituximab 500 mg/50 mL Injection, Enfiera Rituximab Injection, Anti-CD20 Monoclonal Antibody Injection